



Current knowledge on the genetics of autism and propositions for future research.

Thomas Bourgeron

► To cite this version:

Thomas Bourgeron. Current knowledge on the genetics of autism and propositions for future research.. Comptes Rendus Biologies, 2016, 339 (7-8), pp.300-7. 10.1016/j.crv.2016.05.004 . pasteur-01578113

HAL Id: pasteur-01578113

<https://pasteur.hal.science/pasteur-01578113>

Submitted on 28 Aug 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License



Trajectories of genetics, 150 years after Mendel/Trajectoires de la génétique, 150 ans après Mendel

Current knowledge on the genetics of autism and propositions for future research



Les connaissances actuelles sur la génétique de l'autisme et propositions pour la recherche future

Thomas Bourgeron^{a,b,c,*}

^a Human Genetics and Cognitive Functions Unit, Institut Pasteur, 75015 Paris, France

^b CNRS UMR3571, Genes, Synapses and Cognition, Institut Pasteur, 75015 Paris, France

^c Human Genetics and Cognitive Functions, Paris Diderot University, Sorbonne Paris Cité, 75013 Paris, France

ARTICLE INFO

Article history:

Received 26 March 2016

Accepted after revision 24 April 2016

Available online 8 June 2016

Keywords:

Autism Spectrum disorders

Twin studies

Heritability

CNV

SNV

Synapse

ABSTRACT

Autism spectrum disorders (ASD) are a heterogeneous group of neuropsychiatric disorders characterized by problems in social communication, as well as by the presence of restricted interests, stereotyped and repetitive behaviours. In the last 40 years, genetic studies have provided crucial information on the causes of ASD and its diversity. In this article, I will first review the current knowledge on the genetics of ASD and then suggest three propositions to foster research in this field. Twin and familial studies estimated the heritability of ASD to be 50%. While most of the inherited part of ASD is captured by common variants, our current knowledge on the genetics of ASD comes almost exclusively from the identification of highly penetrant *de novo* mutations through candidate gene or whole exome/genome sequencing studies. Approximately 10% of patients with ASD, especially those with intellectual disability, are carriers of *de novo* copy-number (CNV) or single nucleotide variants (SNV) affecting clinically relevant genes for ASD. Given the function of these genes, it was hypothesized that abnormal synaptic plasticity and failure of neuronal/synaptic homeostasis could increase the risk of ASD. In addition to these discoveries, three propositions coming from institutions, researchers and/or communities of patients and families can be made to foster research on ASD: (i) to use more dimensional and quantitative data than diagnostic categories; (ii) to increase data sharing and research on genetic and brain diversity in human populations; (iii) to involve patients and relatives as participants for research. Hopefully, this knowledge will lead to a better diagnosis, care and integration of individuals with ASD.

© 2016 Académie des sciences. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

* Human Genetics and Cognitive Functions Unit, Institut Pasteur, Paris, France.

E-mail address: thomas.bourgeron@pasteur.fr.

R É S U M É

Mots clés :

Troubles du spectre autistique
Études de jumeaux
Héritabilité
CNV
SNV
Synapse

Les troubles du spectre autistique (TSA) sont un groupe hétérogène de troubles neuropsychiatriques caractérisés par des problèmes de communication sociale, ainsi que par la présence d'intérêts restreints et de comportements stéréotypés et répétitifs. Au cours des 40 dernières années, les études génétiques ont fourni des informations cruciales sur les causes des TSA et leurs diversités. Dans cet article, je vais d'abord examiner les connaissances actuelles sur la génétique des TSA, puis suggérer trois propositions pour encourager la recherche dans ce domaine. Les études familiales et de jumeaux ont permis d'estimer l'héritabilité des TSA à 50 %. Alors que la plupart de la partie héritée des TSA est due à des variants communs, nos connaissances actuelles sur la génétique des TSA vient presque exclusivement de l'identification de mutations *de novo* très pénétrantes à l'aide d'études de gènes candidats ou de séquençage d'exome/génome entier. Environ 10 % des patients atteints de TSA, en particulier ceux qui ont une déficience intellectuelle, sont porteurs de mutations *de novo* de nombre de copies (CNV) ou de changements de nucléotides (SNV) affectant des gènes cliniquement pertinents pour les TSA. Compte tenu de la fonction de ces gènes, il a été émis l'hypothèse qu'une plasticité synaptique anormale et un défaut de l'homéostasie neuronale/synaptique pourrait augmenter le risque de TSA. En plus de ces découvertes, trois propositions provenant des institutions, des chercheurs et/ou des communautés de patients et des familles peuvent être formulées pour encourager la recherche sur les TSA : (i) utiliser des données plus dimensionnelles et quantitatives que les catégories de diagnostic ; (ii) augmenter le partage des données et la recherche sur la diversité génétique et le cerveau dans les populations humaines ; (iii) impliquer les patients et leurs familles en tant que participants à la recherche. En espérant que cette connaissance conduira à de meilleurs diagnostics, de meilleurs soins et une meilleure intégration des personnes atteintes de TSA.

© 2016 Académie des sciences. Publié par Elsevier Masson SAS. Cet article est publié en Open Access sous licence CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Autism spectrum disorders (ASD) are a group of neuropsychiatric disorders characterized by problems in social communication, as well as the presence of restricted interests, stereotyped and repetitive behaviours [1,2]. Epidemiological studies estimate that more than 1% of the population could receive a diagnosis of ASD [3]. Individuals with ASD can also suffer from other psychiatric and medical conditions including intellectual disability (ID), epilepsy, motor control difficulties, attention-deficit hyperactivity disorder (ADHD), tics, anxiety, sleep disorders, depression or gastrointestinal problems [4]. The term ESSENCE for 'Early Symptomatic Syndromes Eliciting Neurodevelopmental Clinical Examinations' was coined by Christopher Gillberg to take into account this clinical heterogeneity and syndrome overlap [4]. There are 4–8 times more males than females in ASD, but the sex ratio is more balanced in patients with ID and/or dysmorphic features. Autism can be studied as a category (affected vs. unaffected) or as a quantitative trait using auto- or hetero-questionnaires such as the social responsiveness scale (SRS) or the autism quotient (AQ). Using these tools, autistic traits seem to be normally distributed in clinical cases as well as in the general population.

The causes of autism remain largely unknown, but twin studies have constantly shown a high genetic contribution to ASD. Molecular genetic studies have identified more than 100 ASD-risk genes carrying rare and penetrant deleterious mutations in approximately 10–25% of the patients [5]. In addition, quantitative genetic studies have

shown that common genetic variants could capture almost all the heritability of ASD [5]. The genetic landscape of ASD is therefore shaped by a complex interplay between common and rare variants and is most likely different from one individual to another [6]. Remarkably, the susceptibility genes seem to converge in a limited number of biological pathways including chromatin remodelling, protein translation, actin dynamics, and synaptic functions [6].

In this chapter, I will detail the advances of the genetics of ASD in the last four decades starting from twin studies, following with molecular genetics and neurobiological studies (Fig. 1) and end with propositions to foster research in this field.

2. Twin and family studies in ASD

Based on more than 13 twin studies, published between 1977 and 2015, researchers have estimated the genetic and environmental contribution to ASD (Fig. 2). In 1977, the first twin study of autism by Folstein and Rutter reported a cohort of 11 monozygotic (MZ) twins and 10 dizygotic (DZ) twins. This study showed that MZ twins were more concordant for autism in 36% (4/11) compared with 0% (0/10) for DZ twins. When a "broader autism phenotype" was used, the concordance increased to 92% for MZ twins and to 10% for DZ twins. Since this first small-scale study, twin studies have constantly reported higher concordance for ASD in MZ compared with DZ twins. Between 2005 and 2009, three twin studies with relatively large group of twins (up to more than 3000 twin pairs) have reported




Fig. 1. The history of the genetics of autism from 1975 to 2015. The increase in the number of genes associated with ASD (SFARI, March 2015) is represented together with the prevalence of ASD (data taken from the Center for Disease Control and Prevention), the different versions of the Diagnostic Statistical Manual (from DSM II to DSM-5.0), and the advance in genetics technology.




Fig. 2. The main twins studies in ASD. A total of 13 twin studies and 17 heritability studies are depicted. Means of concordance and heritability weighted by sample size are presented on the right-hand side of the figure.

high concordances for ASD in MZ twins (77–95%) compared with DZ twins (31%). Interestingly, a significant proportion of the genetic contribution to ASD is shared with other neurodevelopmental disorders such as ADHD (> 50%) and learning disability (> 40%) [7]. In summary,

when all twin studies are taken into account, concordance for ASD is roughly 45% for MZ twins and 16% for DZ twins.

Family studies also revealed that the recurrence of having a child with ASD increases with the proportion of the genome that the individual shares with one affected

sibling or parent. In a population-based sample of 14,516 children diagnosed with ASD [8], the relative risk for ASD (compared to the general population) was estimated to be 153.0 (95% confidence interval (CI): 56.7–412.8) for MZ twins, 8.2 (3.7–18.1) for DZ twins, 10.3 (9.4–11.3) for full siblings, 3.3 (95% CI: 2.6–4.2) for maternal half siblings, 2.9 (95% CI: 2.2–3.7) for paternal half siblings, and 2.0 (95% CI: 1.8–2.2) for cousins. The heritability was estimated to be 50% (95% CI: 45–56), and the non-shared environmental influence was also 50% (95% CI: 44–55). Surprisingly, only the additive genetic component and the non-shared environment seemed to account for the risk to develop ASD [8].

In summary, epidemiological studies have provided crucial information on the heritability of ASD. However, they do not inform us on the genes involved or on the number and frequency of their variants. In the last 15 years, candidate genes and whole-genome analyses have been performed to address these questions.

3. From chromosomal rearrangements to copy-number variants in ASD

The first genetic studies that associated genetic variants with autism used observations from cytogenetic studies. However, because of the low resolution of the karyotypes, it was almost impossible to associate a specific gene with ASD using this approach. The prevalence of large chromosomal abnormalities is estimated to be less than 2%. Thanks to progress in molecular technologies, the resolution in the detection of genomic imbalances has dramatically increased. Nowadays, the copy-number variants (CNVs)—that are small gain or loss of genomic DNA—are robustly detected. *De novo* CNVs are present in 4–7% of the patients with ASD compared with 1–2% in unaffected siblings and controls [9]. Beyond ASD, large CNVs (> 400 kb) affecting genes are present in 15% of patients with developmental delay (DD) or ID. Most of the CNVs are private to each individual, but some are recurrently observed in independent patients. The studies have also indicated that *de novo* CNVs identified in patients with ASD are most likely altering genes associated with synaptic functions [9].

In summary, large chromosomal rearrangements and CNVs increase the risk of having ASD in 5–10% of the individuals. In order to go further in the identification of the ASD-risk genes, candidate genes and whole exome/genome sequencing studies were performed.

4. From candidate genes to whole exome/genome sequencing studies in ASD

The first approach to associate a gene with ASD was to select specific candidate genes based on data coming from functional or genetic studies or a combination of both. This approach was successful in identifying several synaptic genes associated with ASD such as *NLGN3*, *NLGN4X* and *SHANK3* [10,11]. Thanks to the advance in next-generation sequencing (NGS), we can now interrogate all genes of the genome in an unbiased manner using whole exome/genome sequencing (WES, WGS). These approaches allow

the identification of virtually all the mutations within genes carried by an individual.

To date, more than 18 of such WES/WGS studies have been performed, comprising altogether more than 4000 families. Based on these studies, 3.6–8.8% of the patients were shown to carry a *de novo* causative mutation with a twofold increase of deleterious mutations in the patients compared with their unaffected siblings. In a meta-analysis, using more than 2500 families, Iossifov *et al.* [12] found that *de novo* likely gene disrupting mutations (frameshift, nonsense and splice site) were more frequent in patients with ASD compared with unaffected siblings ($P = 5 \times 10^{-7}$). The carriers of these *de novo* mutations were more likely diagnosed with a low non-verbal IQ. Interestingly, the mutations were significantly enriched in genes involved in chromatin modelling factors ($P = 4 \times 10^{-6}$) and in genes regulated by the fragile X syndrome protein (FMRP) complex ($P = 4 \times 10^{-7}$).

Only few studies have analysed the contribution of recessive inherited mutations in ASD. It was estimated that likely gene disrupting mutations (present on both paternal and maternal chromosomes) could account for 3% of the patients with ASD. For the X chromosome, there was a significant 1.5-fold increase in complete loss of function mutations in affected males compared to unaffected males, who could account for 2% of males with ASD [13].

5. The common variants in ASD

In the general population, one individual carries on average 3 million genetic variants in comparison to the reference human genome sequence. The vast majority of the variants (> 95%) are the so-called common variants shared with more than 5% of the human population. Using quantitative genetics, it was estimated that common variants were contributing to a high proportion of the liability of ASD: 40% in simplex families and 60% in multiplex families. In 2014, the study of Gaugler *et al.* provided an estimation of the heritability (52.4%), which is almost exclusively due to common variation, leaving only 2.6% of the liability to the rare variants [14]. These results indicate that the contribution of common variants is important, but the causative SNPs still remain unknown since they are numerous (> 1000) and each associated with a low risk. To date, the largest genome wide association studies (GWAS) performed on < 5000 families with ASD were underpowered to identify a single SNP with genome wide significance. The recruitment of larger cohorts of patients with dimensional phenotypes is warranted to better ascertain the heritability of ASD and to identify the genetic variants, which explain most of the genetic variance.

6. The genetic architecture of ASD: an interplay between rare and common variants

Based on the results coming from epidemiological and molecular studies, it is now well accepted that genetic factors play an important role in the susceptibility to ASD. It was also shown that the genetic susceptibility to ASD could be different from one individual to another with a combination of rare deleterious variants and a myriad of

low-risk alleles (also defined as the genetic background). For some individuals, a single *de novo* mutation will be enough to cause autism. For some individuals, the accumulation of many (> 1000) common risk alleles will additively increase the risk of autism.

The interplay between the rare or *de novo* variants and the background will also influence the phenotypic diversity observed in the patients carrying rare deleterious mutations. In some individuals, a genetic background will be able to buffer or compensate the impact of the rare genetic variations. In contrast, in some individuals, the buffering capacity of the genetic background will not be sufficient to compensate the impact of the deleterious mutations and they will develop ASD. In this model, ASD can be regarded as a collection of many genetic forms of autism, each with a different aetiology ranging from monogenic to polygenic models.

Fortunately, although the ASD-risk genes are numerous, they seem to converge in a limited number of biological pathways that are currently scrutinized by many researchers.

7. The biological pathways associated with ASD

Based on results from the genetics of ASD, cellular and animal models have been analysed in order to identify the main mechanisms leading to this complex syndrome. Remarkably, several studies showed that neuronal activity seems to regulate the function of many of the ASD-risk genes. This has led to the hypothesis that abnormal synaptic plasticity and failure of neuronal/synaptic homeostasis could play a key role in the susceptibility to ASD. Fig. 3 summarizes the main genes/pathways associated with ASD: *chromatin remodelling, protein synthesis, protein degradation, and synaptic function* (Fig. 3).

8. Perspectives: three propositions to improve research on autism

While tremendous progress has been made in the understanding of the causes of autism, I will detail three propositions that could foster the research in the field.

8.1. Proposition #1: fewer categories, more dimensions

The recent advances in genomics have demonstrated that an identical genetic variant may increase the risk for a wide range of diagnoses formerly thought of as distinct. These findings are contributing to a re-conceptualization of the current psychiatric nosology. The fifth edition of the Diagnostic and Statistical Manual (DSM-5) from the American Psychiatric Association now makes it easier to recognize overlap between different diagnostic categories, but in the main, the existing narrow and rigid categories tend to disconnect researchers from the real phenotypes. Recently, several initiatives such as the ESSENCE from Christopher Gillberg were undertaken to improve phenotype characterization using more dimensional approaches. The Research Domain Criteria (RDoC) has been launched by NIMH calling for the development, for research purposes, of new ways of classifying psychopathology based on

dimensions of observable behaviour and neurobiological and genetic measures (<http://www.nimh.nih.gov/research-priorities/rdoc/nimh-research-domain-criteria-rdoc.shtml>). This effort is attempting to define basic dimensions of functioning related to known neural circuitry to be studied across multiple units of analysis, from genes to neural circuits to behaviours, cutting across disorders as traditionally defined.

In summary, it is most likely that progress in the comprehension of the risk factors for autism will come from dimensional and quantitative data that goes well beyond current psychiatric classification. One first step would be to gather the information that is currently separated by DSM-5 diagnostic categories and dispersed in different laboratories that may fail to communicate. To achieve this, there is a need of more data sharing (see below).

8.2. Proposition #2: more research on genetic and brain diversity in human populations and more data sharing

Based on current case-control design, there is a tendency for researchers to know better the genotypes and phenotypes of the patients than those of the controls. Indeed, in the vast majority of the genetic studies, controls are often not investigated at the phenotypic level, and in phenotypic studies, controls are very limited in their number and cultural and social economic status diversity. As a consequence, early onset developmental disorders are therefore considered as binary traits “affected” vs. “non-affected” without taking into account the genetic and phenotypic diversity of both “affected” and “non-affected” individuals.

Integrating diversity in our experimental design will require increasing the sample size of our study populations. Indeed, risk factors for early onset neurodevelopmental disorders are either rare with large effect or frequent, but with a small effect. In both situations, robust genotype–phenotype relationships are difficult to ascertain in small samples. One opportunity to increase sample size is to foster data sharing. Many brakes reduce efficient data sharing. Hence, there is a need:

- to agree on an ethical informed consent for research subjects that will allow data sharing;
- to agree on standardized measures;
- to change the reward system regarding publications;
- to set up a system to make data sharing easy and secure.

There is an emerging community of researchers involved in data sharing. Specifically in neuroscience, initiatives such as the Neuroscience Information Framework (NIF) or the International Neuroinformatics Coordinating Facility (INCF) were launched recently. NIF (<http://www.neuinfo.org>) is a dynamic inventory of Web-based neuroscience resources: data, materials, and tools accessible via any computer connected to the Internet. This should advance neuroscience research by enabling discovery and access to public research data and tools worldwide through an open source, networked environment. INCF




Fig. 3. Examples of the biological pathways associated with ASD. The ASD-risk genes code for proteins involved in chromatin remodeling, transcription, protein synthesis, and degradation, cytoskeleton dynamics, and synaptic functions. Proteins associated with ASD are circled in red.

(<http://www.incf.org/>) develops a collaborative neuroinformatics infrastructure and promotes the sharing of data and computing resources with the international research community.

8.3. Proposition #3: patients and relatives as participants for research

Many aspects on the quality of life of the patients and their relatives are not adequately taken into account by researchers. For example, in ASDs, comorbidities such as gastrointestinal and sensory problems are under-explored. The movement “no research about me, without me” is calling for patients and their relatives to be more involved in research designs. For example, the UK National health Service (NHS) initiative INVOLVE (<http://www.invo.org.uk>) is a national advisory group that supports greater public involvement in NHS, public health and social care research. There is also the James Lind Alliance (<http://www.lindalliance.org>), the Patient-Centered Outcomes Research Institute (PCORI; <http://www.pcori.org>), and PatientsLikeMe (<http://www.patientslikeme.org>) initiatives for patients that want to monitor their own health and chronic illness. Another example is the initiative for Cancer research at Sage Bionetworks (<http://www.sagebase.org>). SAGE develops tools so that medical patients can keep their own data rather than storing that data in particular medical institutions. The aim is to offer predictive, personalized, preventive, participatory (P4) medicine.

9. Conclusion: towards a more inclusive world

In the last 40 years, very significant progresses were made in the genetics of ASD. We have now a better knowledge of the genetic architecture of this heterogeneous syndrome and some of the biological pathways are now investigated using different approaches such as cellular and animal models. There are however many aspects of the genetics of ASD that remain largely unknown.

The first challenge concerns the role of the common variants. These variants are most likely playing a key role in the susceptibility to ASD and in the severity of the symptoms. But, because the impact of each single SNP is very low, it is currently impossible to identify the risk alleles using conventional GWAS. In human quantitative traits such as height, neuroanatomical diversity or intelligent quotient, very large cohorts of many thousands of individuals are necessary to identify the main causative SNPs.

The second challenge concerns the stratification of the patients and the role of the ASD-risk genes during brain development/function. Based on our current knowledge, the genetic architecture of ASD seems to be different from one individual to another with possibly contrasting impact on when and where neuronal connectivity could be atypical compared to the general population. For example, in animal models, several mutations lead to higher connectivity whereas other mutations alter synaptic density. It is therefore crucial to increase our knowledge from a basic research perspective on the biological roles of the ASD-risk genes and their partners.

Finally, while we all agree that biological research is necessary to improve the quality of life of the patients and their families, progress should also be made for a better recognition and inclusion of people with neuropsychiatric conditions in our societies (no mind left behind). For patients, the burden of neurodevelopmental disorders makes daily activities difficult and lowers the odds of living an independent life. In addition to improved medical care, innovative initiatives towards a more inclusive world point toward other important advances. For example, Aspiritech (<http://www.aspiritech.org>), a non-profit organization based in Highland Park, Illinois, places people who have autism (mainly Asperger's syndrome) in software testing jobs. The Danish company Specialisterne has helped more than 170 individuals with autism obtain jobs since 2004. Its parent company, the Specialist People Foundation, aims to connect one million autistic people with meaningful work (<http://www.specialistpeople.com>). Laurent Mottron, a psychologist working in Montréal, has offered jobs for patients with ASD in his group and this new perspective has had a positive impact on his research on autism. As he said, “The hallmark of an enlightened society is its inclusion of non-dominant behaviours and phenotypes, such as homosexuality, ethnic differences and disabilities. Governments have spent time and money to accommodate people with visual and hearing impairments, helping them to navigate public places and find employment, for instance—we should take the same steps for autistics” [15]. As suggested by Gillberg, it might be better to abandon the belief that there is a single defining ASD brain dysfunction. Instead, we should understand the diversity of ASD (or autisms). Considering autism not as a single entity, but as a continuum of human diversity and tackling this heterogeneity using information coming from different fields of research (including direct information from the affected individuals and their family) should allow a better diagnosis, care and integration of individuals with autism [15].

Disclosure of interest

The author declares that he has no competing interest.

Acknowledgements

I thank Guillaume Huguet for drawing the figures. This work was funded by the Institut Pasteur, the Bettencourt-Schueller foundation, the “Centre national de la recherche scientifique”, Paris Diderot University, the “Agence nationale de la recherche” (SynDiv-ASD), the GenMed labex, the BioPsy labex, the Conny-Maeva Charitable Foundation, the Cognacq-Jay Foundation, the Orange Foundation, and the Fondamental Foundation.

References

- [1] L. Kanner, Autistic disturbances of affective contact, *Nerv. Child* 2 (1943) 217–250.
- [2] H. Asperger, Die “autistischen Psychopathen” im Kindesalter, *Arch. Psychiatr. Nervenkr.* 177 (1944) 76–137.

- [3] I. Developmental Disabilities Monitoring Network Surveillance Year Principal, Prevalence of autism spectrum disorder among children aged 8 years—autism and developmental disabilities monitoring network, 11 sites, United States, 2010, *MMWR Surveill. Summ.* 63 (Suppl. 2) (2014) 1–21.
- [4] C. Gillberg, The ESSENCE in child psychiatry: early symptomatic syndromes eliciting neurodevelopmental clinical examinations, *Res. Dev. Disabil.* 31 (2010) 1543–1551.
- [5] G. Huguet, E. Ey, T. Bourgeron, The genetic landscapes of autism spectrum disorders, *Annu. Rev. Genomics Hum. Genet.* 14 (2013) 191–213.
- [6] T. Bourgeron, From the genetic architecture to synaptic plasticity in autism spectrum disorder, *Nat. Rev. Neurosci.* 16 (2015) 551–563.
- [7] A. Ronald, R.A. Hoekstra, Autism spectrum disorders and autistic traits: a decade of new twin studies, *Am. J. Med. Genet. B Neuropsychiatr. Genet.* 156B (2011) 255–274.
- [8] S. Sandin, P. Lichtenstein, R. Kuja-Halkola, H. Larsson, C.M. Hultman, A. Reichenberg, The familial risk of autism, *JAMA* 311 (2014) 1770–1777.
- [9] D. Pinto, E. Delaby, D. Merico, et al., Convergence of genes and cellular pathways dysregulated in autism spectrum disorders, *Am. J. Hum. Genet.* 94 (2014) 677–694.
- [10] S. Jamain, H. Quach, C. Betancur, et al., Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism, *Nat. Genet.* 34 (2003) 27–29.
- [11] C.M. Durand, C. Betancur, T.M. Boeckers, et al., Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders, *Nat. Genet.* 39 (2007) 25–27.
- [12] I. Iossifov, B.J. O’Roak, S.J. Sanders, et al., The contribution of *de novo* coding mutations to autism spectrum disorder, *Nature* 515 (2014) 216–221.
- [13] N. Krumm, T.N. Turner, C. Baker, et al., Excess of rare, inherited truncating mutations in autism, *Nat. Genet.* 47 (2015) 582–588.
- [14] T. Gaugler, L. Klei, S.J. Sanders, et al., Most genetic risk for autism resides with common variation, *Nat. Genet.* 46 (2014) 881–885.
- [15] L. Mottron, Changing perceptions: the power of autism, *Nature* 479 (2011) 33–35.